• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase Forward Revenue, Profits Jump

Phase Forward Revenue, Profits Jump

July 25, 2007
CenterWatch Staff

Waltham, Mass.-based Phase Forward, a provider of electronic data capture (EDC), drug safety and data management solutions for clinical trials, reported second quarter revenues rose 28% to $31.5 million and profits doubled.

At mid-day, Phase Forward's shares were up 11% to $18.18.

For the second quarter, income from operations increased 89% from the prior year period to $4.5 million, resulting in a 14.4% operating margin. Net income for the period was $5.6 million, or $0.14 per diluted share, compared with $2.7 million, or $0.07 per diluted share, in the second quarter of 2006.

License, application hosting and other related revenues increased 39% to $22.8 million from $16.3 million in the prior year period, representing 72% of second quarter 2007 total revenues.

"We are pleased with the company's performance during the second quarter, which was highlighted by major customer wins, new and expanded partnerships with contract research organizations (CROs), a breakthrough technology introduction and an increase in the level of competitive replacement activity. We continue to be encouraged by the overall strength of market demand for EDC and safety solutions, which is reflected in our increased outlook for bookings in 2007," said Bob Weiler, chief executive officer and president of Phase Forward.

During the second quarter, a top 10 pharmaceutical company expanded its adoption of Phase Forward’s EDC solution into a multi-year, multi-million dollar application services provider commitment.

“We believe the increasing adoption of EDC by the world's largest pharmaceutical companies adds further pressure on other companies to make similar investments or risk being at a competitive disadvantage. Phase Forward is benefiting from this trend due to our customer reference ability, proven scalability, global service and support infrastructure, as well as the breadth and depth of our products' functionality. In addition, our recently introduced Central Designer(TM) application can help customers shorten the EDC study design and build process more effectively, improving operational efficiencies and reducing the barriers to adoption for customers of all sizes," Weiler added.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing